Form 4: Amylyx Pharmaceuticals Chief Legal Officer Gifts 1,000 Shares

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, reported gifting 1,000 shares of common stock on May 22, 2025, for no consideration.

Summary

• Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a disposition of 1,000 shares of common stock.
• The transaction occurred on May 22, 2025, and was classified as a bona fide gift for no consideration.
• Following this transaction, Ms. Mazzariello directly beneficially owns 186,969 shares of Amylyx Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The transaction represents a gift of a small number of shares by an insider, which is a routine event and does not significantly alter the company's financial or operational outlook. It is considered neutral.

Negatives

• The transaction represents a reduction of 1,000 shares in the direct beneficial ownership of common stock by a key executive, Gina Mazzariello.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape within the pharmaceutical sector.

Related Party Transactions

• The transaction involves a bona fide gift of shares for no consideration by a Chief Legal Officer, which is a form of related party transaction if the recipient is a related party, though the recipient is not disclosed in this filing.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small volume of shares involved relative to the company's total outstanding shares.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Insider Transaction, Gina Mazzariello, Chief Legal Officer, Share Gift, Beneficial Ownership